The Library
The Cambridge post-mastectomy radiotherapy (C-PMRT) index : a practical tool for patient selection
Tools
Mukesh, Mukesh B., Duke, Simon, Parashar, D., Wishart, Gordon, Coles, Charlotte E. and Wilson, Charles (2014) The Cambridge post-mastectomy radiotherapy (C-PMRT) index : a practical tool for patient selection. Radiotherapy and Oncology, 110 (3). pp. 461-466. doi:10.1016/j.radonc.2013.09.024 ISSN 0167-8140.
|
PDF
WRAP_PIIS0167814013005161.pdf - Requires a PDF viewer. Available under License Creative Commons Attribution Non-commercial Share Alike. Download (637Kb) | Preview |
Official URL: http://dx.doi.org/10.1016/j.radonc.2013.09.024
Abstract
BACKGROUND AND PURPOSE:
Post mastectomy radiotherapy (PMRT) reduces loco-regional recurrence (LRR) and has been associated with survival benefit. It is recommended for patients with T3/T4 tumours and/or ⩾ 4 positive lymph nodes (LN). The role of PMRT in 1-3 positive LN and LN negative patients is contentious. The C-PMRT index has been designed for selecting PMRT patients, using independent prognostic factors for LRR. This study reports a 10 year experience using this index.
MATERIALS AND METHODS:
The C-PMRT index was constructed using the following prognostic factors (a) number of positive LN/lymphovascular invasion, (b) tumour size (c) margin status and (d) tumour grade. Patients were categorised as high (H) risk, intermediate (I) risk and low (L) risk. PMRT was recommended for H and I risk patients. The LRR, distant metastasis and overall survival (OS) rates were measured from the day of mastectomy.
RESULTS:
From 1999 to 2009, 898 invasive breast cancers in 883 patients were treated by mastectomy (H: 323, I: 231 and L: 344). At a median follow up of 5.2 years, 4.7% (42/898) developed LRR. The 5-year actuarial LRR rates were 6%, 2% and 2% for the H, I and L risk groups, respectively. 1.6% (14/898) developed isolated LRR (H risk n = 4, I risk group n = 0 and L risk n = 10). The 5-year actuarial overall survival rates were 67%, 77% and 90% for H, I and L risk groups, respectively.
CONCLUSION:
Based on published literature, one would have expected a higher LRR rate in the I risk group without adjuvant RT. We hypothesise that the I risk group LRR rates have been reduced to that of the L risk group by the addition of RT. Apart from LN status and tumour size, other prognostic factors should also be considered in selecting patients for PMRT. This pragmatic tool requires further validation.
Item Type: | Journal Article | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) | ||||||||||
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences > Cancer Research Unit Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||||||||
Library of Congress Subject Headings (LCSH): | Breast -- Radiography, Radiotherapy, Mastectomy | ||||||||||
Journal or Publication Title: | Radiotherapy and Oncology | ||||||||||
Publisher: | Elsevier Science BV | ||||||||||
ISSN: | 0167-8140 | ||||||||||
Official Date: | March 2014 | ||||||||||
Dates: |
|
||||||||||
Volume: | 110 | ||||||||||
Number: | 3 | ||||||||||
Page Range: | pp. 461-466 | ||||||||||
DOI: | 10.1016/j.radonc.2013.09.024 | ||||||||||
Status: | Peer Reviewed | ||||||||||
Publication Status: | Published | ||||||||||
Access rights to Published version: | Open Access (Creative Commons) | ||||||||||
Funder: | Medical Research Council (Great Britain) (MRC), Cancer Research UK (CRUK), Cambridge National Institute of Health Research Biomedical Research Centre, Medical Research Council Biostatistics Unit | ||||||||||
Grant number: | 09/150/16, RG49390 (CRUK), G0800860 | ||||||||||
Adapted As: |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |
Downloads
Downloads per month over past year